Using coverage and claims data provides pharma a view of payer and prescriber behavior

Published on January 30, 2023

Insufficient return on investment due to an underperforming launch is a thought that makes any pharma manufacturer shudder. Considering that about half of all products launched over the last 15 years have underperformed pre-launch consensus forecasts by more than 20%, companies must proactively plan their near- and long-term strategies to ensure financial losses remain a […]

Continue reading on website
Other news

FDA Modernization Act 2.0: FDA no longer requires all drugs to be tested on animals before human trials

January 30, 2023
Animal testing has been a regulatory requirement since 1938 to determine the safety and efficacy of drugs before they enter clinical trials. Despite the fact that animal models have uncovered many disease mechanisms, physiological and genetic differences between animals and humans often result in failures during clinical trials, with significant consequences. Between 2007 and 2010, 66% of Phase II

Emerus Surpasses Three Million Patients Treated

February 1, 2023
Strong Health System Partnerships Fuel Innovative Company’s Impressive GrowthHOUSTON – Feb. 1, 2023 – The successes keep coming for fast-growing Emerus Holdings Inc., the nation’s first and largest operator of small-format hospitals that are known across the country as neighborhood or community hospitals. Emerus, along with its 10 leading health system partners, has achieved the milestone of treat